4-amino-5-(furan-2-yl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine | 622381-06-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 吡咯并嘧啶核苷和核苷酸
• 英文名称: 4-amino-5-(furan-2-yl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 2-(4-amino-5-furan-2-yl-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol；(2R,3R,4S,5R)-2-[4-amino-5-(2-furyl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol；(2R,3R,4S,5R)-2-[4-amino-5-(furan-2-yl)pyrrolo[2,3-d]pyrimidin-7-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 622381-06-0
• 化学式: C₁₅H₁₆N₄O₅
• 分子量: 332.316
• InChiKey: LHLVHKTXINGVSH-SDBHATRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  140
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  2-(4-chloro-5-furan-2-yl-pyrrolo[2,3-d]pyrimidin-7-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 在 氨 作用下， 生成 4-amino-5-(furan-2-yl)-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  [EN] NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION
  [FR] DERIVES NUCLEOSIDIQUES DESTINES AU TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HEPATITE C

  摘要：

  公开号：

  WO2003093290A3

文献信息

• NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES
  申请人：Bourderioux Aurelie

  公开号：US20150218201A1

  公开（公告）日：2015-08-06

  The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.

  本发明提供了式子I的化合物，其中R1、R2和R3的值在规范中定义，并且其药学上可接受的盐；或其光学异构体；或其光学异构体的混合物，以及包含这些化合物的组合物和利用这些化合物和/或组合物的治疗方法。
• 7-deazapurine nucleosides for therapeutic uses
  申请人：Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.

  公开号：US10294262B2

  公开（公告）日：2019-05-21

  The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds and/or compositions.

  本发明提供了式 I 的化合物（其中 R1、R2 和 R3 的值在说明书中定义）及其药学上可接受的盐；或其光学异构体；或光学异构体的混合物，以及包含此类化合物的组合物和利用此类化合物和/或组合物的治疗方法。
• Synthesis and Significant Cytostatic Activity of 7-Hetaryl-7-deazaadenosines
  作者：Aurelie Bourderioux、Petr Nauš、Pavla Perlíková、Radek Pohl、Iva Pichová、Ivan Votruba、Petr Džubák、Petr Konečný、Marián Hajdúch、Kirsten M. Stray、Ting Wang、Adrian S. Ray、Joy Y. Feng、Gabriel Birkus、Tomas Cihlar、Michal Hocek

  DOI：10.1021/jm2005173

  日期：2011.8.11

  A series of 7-aryl- and 7-hetaryl-7-deazaadenosines were prepared by the cross-coupling reactions of unprotected or protected 7-iodo-7-deazaadenosines with (het)arylboronic acids, stannanes, or zinc halides. Nucleosides bearing 5-membered heterocycles at the position 7 exerted potent in vitro antiproliferative effects against a broad panel of hematological and solid tumor cell lines. Cell cycle analysis indicated profound inhibition of RNA synthesis and induction of apoptosis in treated cells. Intracellular conversion to triphosphates has been detected with active compounds. The triphosphate metabolites showed only a weak inhibitory effect on human RNA polymerase II, suggesting potentially other mechanisms for the inhibition of RNA synthesis and quick onset of apoptosis. Initial in vivo evaluation demonstrated an effect of 7-(2-thienyl)-7-deazaadenine ribonucleoside on the survival rate in syngeneic P388D1 mouse leukemia model.
• US9321800B2
  申请人：——

  公开号：US9321800B2

  公开（公告）日：2016-04-26
• US9624257B2
  申请人：——

  公开号：US9624257B2

  公开（公告）日：2017-04-18